El Ethics and Drug Research Committee (CEIm) of Parc Taulí has positioned itself as the first in Catalonia and third in Spain in the evaluation of clinical trials with medicines during 2024, according to the ranking produced annually by theSpanish Agency for Medicines and Health Products (AEMPS).
The list ranks the 25 committees in the State that have carried out the most evaluations of clinical trials with medicines carried out on humans, together responsible for 90% of the evaluation activity currently carried out throughout Spain.
Specifically, last year Parc Taulí resolved a total of 68 projects with clinical trials with medicines, which represents 7% of the total number of projects of these characteristics assessed throughout 2024 in the country, and an increase of 9% compared to the number of projects assessed in 2023 by the same institution.
For Anuska Llano, technical secretary of the committee, "the excellent results obtained cannot be explained without highlighting the great capacity of the team to adapt". And since the entry into operation of the Clinical Trial Information System (CTIS) platform to manage and supervise clinical trials in a coordinated manner between the countries of the European Economic Area, the CEIm of Parc Taulí has been able to adapt its work procedures to a more complex system, guaranteeing quality, safety and efficiency in the evaluation at all times.
Since it was first accredited in 1994 – and subsequently renewed every 4 years – the CEIm of Parc Taulí has become one of the most active nationally in the evaluation of clinical studies. In the period from 2020 to 2024 alone, it has assessed 324 clinical trials with medicines, significantly contributing to the progress of medical research and the development of new therapies to improve the health and well-being of patients.
The functions of the CEIm
The CEIm are accredited independent bodies, in accordance with Royal Decree 1090/2015, to evaluate and issue opinions on clinical studies with medicines and clinical research with health products.
A CEIm evaluates all research that aims to develop drugs for use in humans. Accordingly, it issues an opinion on the trial protocol, the suitability of the research team and facilities, as well as the methodology and documents used to inform trial participants.
CEIm also monitors the clinical trial from start to finish.
You might also like
0 comments
-
-
I3PT communication
Good morning, Arielle. Thank you for your interest.
You can send the information to our email address comunicacioi3pt@tauli.cat and we will manage it internally to be able to give you an answer.
Regards,
-
Arielle Valette
Hi, I'm Arielle Valette. I'm a biologist and I have 20 years of experience in private and public clinical trials. I have a great interest in artificial intelligence and I would like to join an ethics committee to represent the expertise I have and to diversify the expertise of the ethics committee by focusing more on the use of artificial intelligence in clinical trials. thank you